Xenobiotica, Volume 44, Issue 4 (2014)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Xenobiotica, Volume 44, Issue 4 (2014)

See all volumes and issues
Vol 54, 2024 Vol 53, 2023 Vol 52, 2022 Vol 51, 2021 Vol 50, 2020 Vol 49, 2019 Vol 48, 2018 Vol 47, 2017 Vol 46, 2016 Vol 45, 2015 Volume 44, 2014 Vol 43, 2013 Vol 42, 2012 Vol 41, 2011 Vol 40, 2010 Vol 39, 2009 Vol 38, 2008 Vol 37, 2007 Vol 36, 2006 Vol 35, 2005 Vol 34, 2004 Vol 33, 2003 Vol 32, 2002 Vol 31, 2001 Vol 30, 2000 Vol 29, 1999 Vol 28, 1998 Vol 27, 1997 Vol 26, 1996 Vol 25, 1995 Vol 24, 1994 Vol 23, 1993 Vol 22, 1992 Vol 21, 1991 Vol 20, 1990 Vol 19, 1989 Vol 18, 1988 Vol 17, 1987 Vol 16, 1986 Vol 15, 1985 Vol 14, 1984 Vol 13, 1983 Vol 12, 1982 Vol 11, 1981 Vol 10, 1980 Vol 9, 1979 Vol 8, 1978 Vol 7, 1977 Vol 6, 1976 Vol 5, 1975 Vol 4, 1974 Vol 3, 1973 Vol 2, 1972 Vol 1, 1971
Download citations Download PDFs Download issue

General Xenobiochemistry

Article
In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies
Amrita Saxena, Girish K. Jain, Hefazat H. Siddiqui, Shom S. Bhunia, Anil K. Saxena & Jiaur R. Gayen
Pages: 295-308
Published online: 30 Aug 2013
AbstractforIn vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies | Full Text | References | PDF (1 MB)
  • 258 Views
  • 6 CrossRef citations
  • 0Altmetric

Research Article

Article
Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
Mara R. Livezey, Erran D. Briggs, Amanda K. Bolles, Leslie D. Nagy, Rina Fujiwara & Laura Lowe Furge
Pages: 309-319
Published online: 06 Sep 2013
AbstractforMetoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6 | Full Text | References | PDF (721.1 KB) | Supplemental
  • 643 Views
  • 33 CrossRef citations
  • 0Altmetric
Article
Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases
Limei Ai, Liangliang Zhu, Lu Yang, Guangbo Ge, Yunfeng Cao, Yong Liu, Zhongze Fang & Yanyan Zhang
Pages: 320-325
Published online: 25 Sep 2013
AbstractforSelectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases | Full Text | References | PDF (525.4 KB)
  • 479 Views
  • 48 CrossRef citations
  • 0Altmetric
Article
In vitro metabolism of monensin A: microbial and human liver microsomes models
Bruno A. Rocha, Marilda D. Assis, Ana P. F. Peti, Luiz A. B. Moraes, Fernanda L. Moreira, Norberto P. Lopes, Stanislav Pospíšil, Paul J. Gates & Anderson R. M. de Oliveira
Pages: 326-335
Published online: 17 Oct 2013
AbstractforIn vitro metabolism of monensin A: microbial and human liver microsomes models | Full Text | References | PDF (767.2 KB) | Supplemental
  • 314 Views
  • 12 CrossRef citations
  • 0Altmetric
Article
Risk assessment of drug–drug interactions using hepatocytes suspended in serum during the drug discovery process
Yohei Kosugi, Hideki Hirabayashi, Tomoko Igari, Yasushi Fujioka, Teruaki Okuda & Toshiya Moriwaki
Pages: 336-344
Published online: 27 Sep 2013
AbstractforRisk assessment of drug–drug interactions using hepatocytes suspended in serum during the drug discovery process | Full Text | References | PDF (369.1 KB)
  • 396 Views
  • 5 CrossRef citations
  • 0Altmetric
Article
Optimizing the use of rainbow trout hepatocytes for bioaccumulation assessments with fish
Kellie A. Fay, Patrick N. Fitzsimmons, Alex D. Hoffman & John W. Nichols
Pages: 345-351
Published online: 18 Oct 2013
AbstractforOptimizing the use of rainbow trout hepatocytes for bioaccumulation assessments with fish | Full Text | References | PDF (157.1 KB)
  • 244 Views
  • 19 CrossRef citations
  • 0Altmetric

Clinical Pharmacokinetics and Metabolism

Article
Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers
May Y. K. Ho, Michael J. Morris, Jill L. Pirhalla, John W. Bauman, Carolyn B. Pendry, Keith W. Orford, Royce A. Morrison & Donna S. Cox
Pages: 352-368
Published online: 23 Aug 2013
AbstractforTrametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers | Full Text | References | PDF (562.2 KB)
  • 1160 Views
  • 19 CrossRef citations
  • 0Altmetric

Research Article

Article
Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans
Manfred Zell, Christophe Husser, Olaf Kuhlmann, Dietmar Schwab, Takahide Uchimura, Tomonori Kemei, Kosuke Kawashima, Mizuki Yamane & Axel Pähler
Pages: 369-378
Published online: 27 Sep 2013
AbstractforMetabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans | Full Text | References | PDF (330.7 KB)
  • 809 Views
  • 14 CrossRef citations
  • 0Altmetric

Animal Pharmacokinetics and Metabolism

Article
Pharmacokinetic study in pigs and in vitro metabolic characterization in pig- and human-liver microsomes reveal marked differences in disposition and metabolism of tiletamine and zolazepam (Telazol)
Atul Kumar, Henry J. Mann, Rory P. Remmel, Greg J. Beilman & Nitin Kaila
Pages: 379-390
Published online: 11 Sep 2013
AbstractforPharmacokinetic study in pigs and in vitro metabolic characterization in pig- and human-liver microsomes reveal marked differences in disposition and metabolism of tiletamine and zolazepam (Telazol) | Full Text | References | PDF (895.9 KB)
  • 387 Views
  • 8 CrossRef citations
  • 0Altmetric

Explore articles